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ABSTRACT
MicroRNAs (miRNAs) have recently been recognized as targets for anti-metastatic 
therapy against cancer malignancy. Development of effective miRNA mediated 
therapies remains a challenge to both basic research and clinical practice. Here we 
presented the evidence for a miR-708-5p mediated replacement therapy against 
metastatic lung cancer. Expression of miR-708-5p was substantially reduced in 
metastatic lung cancer samples and cancer cell lines when compared to non-metastatic 
counterparts. Expression of the miRNA suppressed cell survival and metastasis  
in vitro through its direct target p21, and inhibited the PI3K/AKT pathway and stem  
cell-like characteristics of lung cancer cells. Systemic administration of this miRNA in a 
mouse model of NSCLC using polyethylenimine (PEI)-mediated delivery of unmodified 
miRNA mimics induced tumor specific apoptosis. It also effectively protected the tested 
animals from developing metastatic malignancy without causing any observed toxicity. 
The findings strongly support miR-708-5p as a novel and effective therapeutic agent 
against metastatic malignancy of non-small cell lung cancer.
INTRODUCTION
Lung cancer is a major cause of death among 
malignant diseases, primarily due to its high incidence, 
malignant behavior and lack of effective treatments [1]. 
Non-small cell lung cancer (NSCLC), accounting for 
~85% of lung cancer incidence, is often diagnosed at an 
advanced stage and has a poor prognosis [2]. Although 
surgery, radiation therapy and chemotherapy can control 
many other primary tumors effectively, these treatments 
have been ineffective in curbing the metastatic spread 
of lung cancer cells [3], creating an urgent need for 
development of more effective therapies against the highly 
metastatic disease. 
miRNAs are small non-coding RNAs responsible 
for regulating more than 70% of human genes. They 
have been increasingly identified as novel biomarkers 
or therapeutic targets [4–7]. miRNAs may act as either 
oncogenes or tumor suppressors, depending on the type 
of tumor or the cellular context [8, 9]. Inactivation of 
oncogenic miRNAs [10, 11] or restoration of tumor 
suppressing miRNAs [12–14] has a great potential for 
cancer treatment, and both strategies have been tested in 
clinical trials [15–19]. However, there has been little or 
no research reported in the literature on miRNA mediated 
prophylactic therapies against lung cancer metastasis.
We detected several significantly differentially 
expressed miRNAs in NSCLC cell lines from TaqMan 
Human MicroRNA Array data [20]. Among them, 
miR-708-5p stood out as a highly expressed miRNA in 
non-metastatic lung cancer cell lines when compared 
with highly metastatic cells. We thoroughly exploited this 
miRNA for its involvement in tumor formation, metastasis 
and apoptosis of NSCLC cells, and tested its potential as a 
therapeutic agent against metastatic NSCLC. 
RESULTS
miR-708-5p expression is associated with 
metastatic status of NSCLC cell lines and tissue 
samples
We identified miR-708-5p for its potential role in 
lung tumor formation, metastasis and apoptosis, based 
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on analysis of TaqMan Human MicroRNA Array data 
from NSCLC cell lines in our previous profiling of 
NSCLC associated miRNAs [20]. To further confirm its 
candidacy, we re-examined expression of miR-708-5p in 
nine NSCLC cell lines varying in their metastatic status. 
Their metastatic status was primarily defined through a 
wound-healing assay and in term of expression profiling 
of the three representative epithelial-to-mesenchymal 
transition (EMT) related marker genes (E-cadherin, 
β-catenin and vimentin), as the EMT has been established 
as a critical event in the invasion, progression and 
metastasis of epithelial cancers [21, 22]. Based on the 
wound-healing assay, four cells (QG56, H520, H2170 
and 95C) were assigned into a low metastatic group 
showing low migration ability, while the other five cell 
lines (PG, H226, A549, H1299 and H1703) formed a high 
metastatic group with high migration ability (Figure 1A). 
These were further corroborated by the western blot assay 
of EMT markers (Figure 1A). qRT-PCR analysis showed 
that expression of miR-708-5p was markedly reduced in the 
high metastatic group when compared to the low metastatic 
ones (Figure 1B). Additionally, we analyzed miR-708-
5p expression in 72 micro-dissected human NSCLC 
tissues (36 adenocarcinomas (Adc) and 36 squamous 
cell carcinomas (Sqc)) by qRT-PCR, which were divided 
into non-metastatic (16 Adc + 16 Sqc) and metastatic 
(20 Adc + 20 Sqc) groups according to the same criterion 
above. Basic clinical characteristics of these samples 
were summarized in Supplementary Table S1. Consistent 
with the cell line analysis, both Adc and Sqc metastasis 
positive tumors showed significant down-regulation of 
miR-708-5p when compared to the non-metastatic tumors 
of the two subtypes (Figure 1C, Supplementary Table S1). 
However, no significant difference was observed in the 
miR-708-5p expression level between age or gender groups 
(Supplementary Table S1). Profiling miR-708-5p expression 
of additional 66 NSCLC samples also independently 
confirmed the inversing correlation between miR-708-5p 
expression and tumor malignancy (Figure 1D). All these 
results strongly support the potential tumor suppressor role 
of miR-708-5p in lung carcinoma. 
To further determine miR-708-5p expression as a 
prognostic biomarker, we investigated the trend of miR-
708-5p expression over the overall survival (OS) among 
the 72 NSCLC patients (Supplementary Table S1). It can 
be seen from Figure 1E that OS of the patients expressing a 
low level of miR-708-5p had a OS median of 15.4 months, 
significantly lower than those expressing a high level of the 
miRNA (OS median of 30.0 months) (log-rank P = 0.014).
Expression of miR-708-5p suppresses lung cancer 
invasion and metastasis in vitro and in vivo
Transfection of miR-708-5p mimics in high 
metastatic PG, A549 and H1299 cells induced cell apoptosis 
(Figure 2A, 2B and Supplementary Figure S1A, S1B). 
Expression of the apoptotic markers, active caspase-3 and 
cleaved PARP, were also found to be up-regulated in these 
cells after transfection with miR-708-5p (Supplementary 
Figure S1C). Furthermore, over-expression of miR-708-
5p in these cells also resulted in weakened migration 
(Supplementary Figure S2A) and invasion by 3–6 fold 
when compared to control cells (Figure 2C), whereas 
down-regulation of miR-708-5p using an antagomir in 
QG56 and 95C cells led to a significant increase in cell 
migration (Supplementary Figure S2B) and invasion by 
2–3 fold when compared to control cells (Figure 2D). The 
miR-708-5p mediated regulation of invasive growth and 
metastasis of lung cancer cells was further supported by 
the observation that the miR-708-5p-induced reduction in 
metastasis was completely abolished in the presence of 
antagomir-708-5p (Figure 2C).
The observed anti-metastasis in vitro motivated us 
to investigate miR-708-5p expression and its effects on 
metastasis in vivo. We used a lentiviral miRNA sponge to 
knock down miR-708-5p stably in QG56 cells with highly 
expressed miR-708-5p, and intravenously injected mice 
with the sponge-control or sponge-miR-708-5p cells. Mice 
in the sponge-miR-708-5p group exhibited considerably 
higher prevalence of metastasis than those in the sponge-
control group. Tumours were found in the lung, heart 
and bone in the sponge-miR-708-5p group (Figure 2E). 
The lungs had an average of 30 visible metastases in the 
sponge-miR-708-5p group, whereas visible metastasis 
was reduced by about 70% in the sponge-control group 
(Figure 2F). These data strongly support miR-708-5p as a 
metastasis suppressor in lung cancer cells in vivo.
p21 is a direct target of miR-708-5p
We implemented bioinformatics algorithms, 
including TargetScan, miRanda and Rna22, to predict 
candidate targets of miR-708-5p, and detected 10 
candidates: CCND3, p21, S1PR1, DRAM1, BAG1, GAS1, 
FLT1, MEN1, p15 and IKBKB, which were directly or 
indirectly associated with metastatic functions such as cell 
proliferation, apoptosis, cell cycle, migration, adhesion, 
invasion and/or cell differentiation. The dual-luciferase 
UTR reporter assay revealed that p21 and S1PR1 showed 
a highly significantly depressed 3′UTR (Supplementary 
Figure S3A). Only the p21 protein levels were significantly 
decreased in A549, H1299 and PG cells expressing 
miR-708-5p (Figure 3A). Further luciferase reporter 
assays showed that miR-708-5p significantly depressed the 
relative luciferase activity of the wild-type 3′UTR of p21 
when compared to that of mutant 3′UTR (Figure 3B and 
Supplementary Figure S3B). Additionally, inhibition of 
miR-708-5p significantly increased the expression of p21 
protein in 95C and QG56 cells (Figure 3C). These findings 
indicate that miR-708-5p directly regulates p21 expression 
through directly targeting its 3′UTR.
To test whether p21 was the direct functional 
mediator of miR-708-5p-induced metastasis and apoptosis 
of lung cancer cells, we employed an expression construct 
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Figure 1: miR-708-5p levels correlate inversely with metastatic ability of NSCLC cell lines and NSCLC tissue samples. 
(A) Assay of metastatic ability in nine NSCLC cell lines. Upper: migration distance (mm) of nine NSCLC cell lines (QG56, H520, 
H2170, 95C, PG, H226, A549, H1299 and H1703). Cells were placed in six-well cell culture plates and their migrations were observed at 
24 and 48 h of the wound healing assay. Shown below is immunoblotting analysis of three representative endogenous EMT marker 
genes (E-cadherin, β-catenin and vimentin) in the NSCLC cell lines. In the analysis, β-actin served as an internal control. (B) miRNA 
qRT-PCR analysis showing significant suppression of miR-708-5p in high-metastatic NSCLC cell lines when compared with low-metastatic 
group. (C) Relative expression of miR-708-5p in 72 NSCLC tissue samples (36 Adc and 36 Sqc) with metastasis (n = 20 Adc + 20 Sqc) 
or non-metastasis (n = 16 Adc +16 Sqc). qRT-PCR analysis shows that miR-708-5p are down-regulated in metastatic tumor samples when 
compared with that in the non-metastatic tissue samples. (D) Relative expression of miR-708-5p in another 66 NSCLC tissue samples 
(28 Adc and 38 Sqc) with metastasis (n = 18 Adc + 9 Sqc) or non-metastasis (n = 10 Adc + 29 Sqc). All miRNA expression levels were 
normalized to the small nuclear RNA U6 and the Mann-Whitney-Wilcoxon test was conducted to infer statistical significance of the miRNA 
expression from the metastatic and non-metastatic groups. (E) Cohort was dichotomized based on miR708-5p median expression and 
presented as a five-year overall Kaplan-Meier survival curves in a panel of patients of NSCLC. Statistical treatment of the data is log-rank. 
P values are indicated on the graph. 
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Figure 2: miR-708-5p induced cell apoptosis and suppressed invasive growth of lung cancer cells. (A) Apoptosis assay 
was performed in the PG cells transfected with either control mimics or miR-708-5p mimics after serum deprivation for 48 h. Upper 
group: altered morphology of the PG cells transfected with the control or miR-708-5p mimics. The assays were assessed by phase-contrast 
microscopy. Scale bars, 80 µm. Lower group: apoptosis assays of the PG cells using the Annexin V/PI kit after the control or miR-708-5p 
mimics treatments and the assays were detected by flow cytometry. (B) Proportions of average apoptosis (including both early and late 
apoptosis) in the two comparing groups of PG cell line. (C) Transwell matrigel invasion assay of the A549, H1299 and PG cells 48 hours 
after transfected with control mimics, miR-708-5p mimics, or miR-708-5p/antago-708-5p (antagomir-708-5p). (D) Transwell matrigel 
invasion assay of the 95C and QG56 cells transfected with antagomir control or antago-708-5p. (C, D) Upper: imagines of the cells 
penetrating through the matrigel after stained with 0.25% Trypan Blue. Scale bars, 250 µm. Lower: means and standard deviations (s.d.) 
of the number of the cells that penetrated through the transwell membrane. (E) Inhibited miR-708-5p promotes metastasis in vivo. Bright-
field imagines (BF) and GFP views of mice surgically examined and their lungs and hearts isolated from the mice that received caudal vein 
injection of the QG56 cells infected with the miR-708-5p sponge or control sponge. (F) The number of metastatic nodules in the lungs of 
mice that received caudal vein injection of the QG56 cells infected with the miR-708-5p sponge or control sponge. Upper: means and s.d. 
of counts of metastatic nidi in the lung tissue slices of the tested mice (n = 6 for each group). Lower: representative H & E stained images 
of lungs showing metastatic nodules. Scale bars, 500 µm.
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in A549 cells which encodes p21 coding sequence but 
lacks the 3′UTR, yielding an mRNA resistant to miRNA-
mediated suppression. Ectopic expression of p21 increased 
migration and invasion in miR-708-5p overexpressing 
A549 cells but not in control cells (Figure 3D). And, 
reduction of active caspase-3/cleaved PARP and apoptosis 
cells confirmed that overexpression of p21 depressed 
apoptosis in both miR-708-5p expressing cells and control 
cells (Figure 3E, 3F, Supplementary Figure S3C). In 
parallel, we synthesized a short interfering RNA (siRNA) 
for p21 and introduced the siRNA into 95C cell line that 
was transfected with antagomir-708-5p. The knockdown 
p21 partially abolished the enhancing effects of miR-708-5p 
antagomir on migration and invasion of the lung cancer cells 
(Figure 3G). And, inhibition of p21 restored cell apoptosis 
in the antagomir-708-5p 95C cells by 80% compared 
with the corresponding control cells (Figure 3H, 3I, 
Supplementary Figure S3D). The bidirectional assays for 
engineering p21 expression both support that the ability of 
miR-708-5p to inhibit metastasis and promote apoptosis is 
attributable to its capacity to depress its target gene p21. We 
conclude that p21 is indeed a direct functional mediator of 
miR-708-5p.
miR-708-5p induces apoptosis and suppresses 
cell migration by inhibiting cytoplasmic 
localization of p21
p21 can localize in the cytoplasm, where it protects 
cells against apoptosis [23] and inhibits Rho-kinase 
activity, affecting the formation of actin stress fibers [24]. 
Notably, cytoskeleton reorganization has been established 
to be essential for cell migration [25]. We firstly examined 
the distribution of p21 in the nucleus and cytoplasm by 
immunoblotting. In the A549 and PG cells transfected 
with miR-708-5p mimics, only was a small amount of p21 
observed in the cytoplasm after serum deprivation when 
compared to the corresponding control cells (Figure 4A). On 
the other hand, cytoplasmic p21 expression was boosted in 
low metastatic 95C cell line when transfected with antagomir-
708-5p (Figure 4A). These support that the cytoplasmic 
localization of p21 was impaired by miR-708-5p.
The cytoplasmic localization of p21 is additionally 
regulated by its phosphorylation at the Thr145 residue 
directed by phosphorylated AKT (pAKT, the activated 
form) [26]. We monitored the protein levels of pT145-p21 
and pS473-AKT1 in A549, H1299 and PG cells expressing 
miR-708-5p. As expected, an increase in miR-708-5p 
expression significantly depressed the protein levels of 
p21, pT145-p21 and pS473-AKT1 (Figure 4B). Since 
pS473-AKT1 is the major effector of the PI3K/AKT 
pathway in cancers [27] and its protein expression was 
reduced in the presence of miR-708-5p, this suggests that 
miR-708-5p could also inhibit the PI3K/AKT pathway. 
Additionally, to further confirm correlation between 
expression of p21, pT145-p21 and PI3K/AKT and 
miR-708-5p expression and metastatic ability, we used 
immunoblotting to evaluate the expression level of p21, 
pT145-p21 and pS473-AKT1 in the nine NSCLC cell lines 
whose expression of miR-708-5p and metastatic ability 
had been confirmed. The results showed that expression 
of p21, pT145-p21 and pS473-AKT1 was negatively 
correlated with expression of miR-708-5p, but positively 
correlated with metastatic ability (Figure 4C). We thus 
conclude that down-regulation of p21 was involved in 
miR-708-5p-suppressed metastasis.
The binding of p21 to procaspase-3 in the 
cytoplasm, rather than to the active caspase-3, is essential 
for resistance to Fas-mediated apoptosis [28]. To evaluate 
whether the blocked p21 cytoplasmic localization by miR-
708-5p would promote cell apoptosis, we carried out a 
co-immunoprecipitation assay to capture the endogenous 
p21/procaspase-3 complexes in the miR-708-5p 
expressing A549 and PG cells and their control cells. The 
assay showed that p21/procaspase-3 binding was markedly 
weakened in the miR-708-5p expressing A549 and PG 
cells when compared to their corresponding control 
cells (Figure 4D, 4E). The co-immunoblotting assay also 
revealed much higher abundance of active caspase-3 in 
the miR-708-5p expressing A549 and PG cells than in the 
control cells (Figure 4D). These observations support the 
blocked cytoplasmic localization of p21 as the mechanism 
responsible for miR-708-5p induced apoptosis.
We used immunocytochemistry to survey 
relationship between cytoplasmic pT145-p21 and the 
actin cytoskeleton in the A549, PG cells transfected 
with miR-708-5p mimics and 95C cells transfected with 
antagomir-708-5p. The miR-708-5p expressing cells 
showed an extensive network of stress fibers, lower 
expression of cytoplasmic pT145-p21, and failed to 
induce the actin rearrangement as observed in the control 
cells (Figure 4F). In contrast, antagomir-708-5p cells had 
markedly fewer actin stress fibers, higher expression of 
cytoplasmic pT145-p21 (Figure 4F). These results suggest 
that cytoskeleton reorganization in lung cancer cells 
may be blocked by miR-708-5p. Taken together, these 
results indicate that miR-708-5p impairs lung cancer cell 
migration and promotes cancer cell apoptosis by inhibiting 
the cytoplasmic localization of p21.
miR-708-5p expression weakens the stem cell 
like properties of lung cancer cells
To determine the cellular pathways regulated by 
miR-708-5p, we identified 599 genes with significant 
differential expression from RNA-seq data of the 
miR-708-5p overexpressing A549 cells and control cells. 
Bioinformatic analysis of global genes using DAVID 
[29] revealed that miR-708-5p may alter the apoptosis 
and migration pathways, including EGF receptor, insulin 
receptor, as well as PI3K/AKT (Figure 5A). Using RNA-
seq data collected from the present study, we selected some 
related genes to further confirm their expression by qRT-
PCR. In agreement with our RNA-seq data, the qRT-PCR 
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Figure 3: p21 is a direct target of miR-708-5p. (A) Immunoblotting for endogenous p21 and S1PR1 proteins in the A549, H1299 
and PG cells transfected with the miR-708-5p or control mimics. β-actin was used as a loading control. (B) Luciferase activity of the wild-
type or mutant p21 3′UTR reporter genes in the 293T cells transfected with the miR-708-5p or control mimics. (C) Immunoblotting of 
p21 in the 95C and QG56 cells transfected with antago-708-5p or control. β-actin was used as a loading control. (D– F) Matrigel invasion 
and apoptosis assay in A549 cells co-transfected with p21 expressing vector or control vector and miR-708-5p or control mimics. (G– I) 
Matrigel invasion and apoptosis in the 95C cells co-transfected with antago-708-5p or antago control and p21 siRNA (si-p21) or control 
siRNA (si-control). (D, G) Upper: inversion imagines of the cells penetrating through the matrigel after stained with 0.25% Trypan Blue. 
Scale bars, 250 µm.  Lower: means and s.d. of the number of the cells penetrating through the transwell membrane. (E, H) Immunoblotting 
of active caspase-3 and cleaved PARP in A549 (E) and 95C (H). (F, I) means and s.d. of fractions of apoptotic cells (early and late apoptosis) 
detected using  Annexin V/PI kit in A549 (F) and 95C (I) cells.
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Figure 4: miR-708-5p inhibits cytoplasmic localization of p21. (A) Subcellular fractionation assay was carried out to 
determine the cellular localization of p21 in the A549 and PG cells transfected with miR-708-5p and control mimics, and 95C cells 
transfected with antago-708-5p and antago-control. Nuclear and cytoplasmic fractions were respectively subjected to immunoblotting 
analysis with antibody against p21. Histone 3 (H3) and β-tubulin were used as loading controls for nuclear and cytoplasmic proteins 
respectively. (B) Immunoblotting of p21, pT145-p21, AKT1 and pS473-AKT1 in the A549, H1299 and PG cells transfected with 
the miR-708-5p mimics, a control miRNA mimics (miR-708-3p) or scramble control mimics. β-actin was used as a loading control. 
(C) Immunoblotting of p21, pT145-p21, AKT1 and pS473-AKT1 in QG56, H520, H2170, 95C, PG, H226, A549, H1299 and H1703 cell lines. 
(D) Co-immunoprecipitation of endogenous p21 and detection of endogenous procaspase-3. The A549 and PG cells, which were serum 
deprived for 48 h, were stimulated by exposure to 10% serum for 6 h. A portion (5%) of the whole cell lysates was used as input for 
the immunoblotting analysis, and β-actin was used as a loading control. (E) Endogenous p21 was immunoprecipitated from 2 mg of 
the protein of A549 and PG cell with the p21 antibody, and probed with p21 and procaspase-3 antibodies in the western blotting assay. 
(F) Confocal images of the A549 and PG cells transfected with the miR-708-5p or control mimics for localization of pT145-p21 and 
cytoskeleton, and 95C cells transfected with antago-708-5p or control. The cells were synchronized after serum deprivation for 48 h and 
then re-stimulated with 10% serum for 6 h. Scale bars, 30 µm.
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assay showed that overexpression of miR-708-5p 
increased expression of the PI3K/AKT pathway repressor 
genes, PIK3IP1, PHLDA3 and INPPL1, but suppressed 
expression of the pathway’s effector genes, BCL2A1, 
BCL2L2 and survivin, in the A549, H1299 and PG cells 
(Figure 5B). Again, the qRT-PCR assay confirmed that the 
genes (MMP2, MMP9, CADM1 and VEGFC) promoting 
metastasis were substantially down-regulated in these miR-
708-5p expressing cells, while E-cadherin, which inhibits 
metastasis, was up-regulated (Figure 5C). Interestingly, 
some cancer stem cell (CSC) associated transcripts, such 
as CD117, CD34, Oct-4, CD44, ALDHA2 and Nanog, 
were down regulated in the A549 and PG cells expressing 
miR-708-5p (Figure 5D). However, no statistically 
significant difference was detected for these genes in the 
H1299 cell line (Supplementary Figure S4). These results 
indicate that miR-708-5p inhibited the lung cancer stem 
cell-like properties. The CSCs have been proposed to be 
responsible for cancer progression and metastasis [30], and 
have great potential for the development of CSC-related 
therapies [31]. We thus proposed here to suppress the 
cancer stem cell like properties through overexpressing 
miR-708-5p in lung cancer cells as a potential new targeted 
therapy against lung cancers.
miR-708-5p mediated replacement therapy in a 
mouse lung tumour model
Based on our in vitro and in vivo assays that 
confirmed the anti-metastatic and anti-cancer stem cell 
activities of miR-708-5p in NSCLC, we tested whether 
synthetic miR-708-5p mimics could have potential for 
replacement therapy in a mouse lung cancer model. We 
firstly explored the antitumor effect of the synthetic miR-
708-5p mimic in the lung cancer xenograft model. Nude 
mice were subcutaneously inoculated with the same volume 
of A549 cells in the right and left flank areas, and then intra-
tumorally administered with miRNA or control mimics 
(fully described in Methods). All mice were sacrificed after 
25 days following inoculation. As shown in Figure 6A and 
Supplementary Figure S5A, mice injected with the PEI/
control showed rapid tumour growth, with an approximately 
20-fold increase in tumour volume over 25 days when 
compared to mice injected with PEI/miR-708-5p. We 
compared expression of the miRNA between the treated 
group and the control group, and observed that the miRNA 
expressed approximately 5000-fold higher in the miR-
708-5p mimic than in the control tumours (Supplementary 
Figure S5B). Additionally, immunohistochemical analysis 
of these tumours revealed significantly increased active 
caspase-3 and decreased expression of p21, pT145-p21, 
and Oct-4 (CSC associated genes) in the tumours injected 
with miR-708-5p (Figure 6B). These observations strongly 
support the marked anti-tumor and anti-cancer stem cell 
effects of the miR-708-5p treatment.
To evaluate the anti-metastatic effects of the miR-
708-5p mimic treatment, we implanted the A549 cells 
with a luciferase reporter into nude mice through tail vein 
injection, as described in Methods. We began the miR-
708-5p replacement treatment at day 3 or day 10 after 
cancer cell implantation. After a 25-day course of delivery 
treatment, in vivo bioluminescence imaging showed that 
administration of PEI/miR-708-5p into mice attenuated 
lung metastases  when the treatment was performed at 
day 3 or day 10 (Figure 6C). To focus on the systemic 
PEI/miR-708-5p delivery, we compared miR-708-5p 
expression in the livers and lungs of animals injected with 
either PEI/miR-708-5p or the PEI/control. The expression 
levels of miR-708-5p in livers and lungs of the PEI/miR-
708-5p group were approximately 30 and 120 fold higher 
than that in the control group, respectively (Supplementary 
Figure S5C, S5D). Thus, systemic delivery of PEI/miR-
708-5p complexes appeared to be a potent approach to 
suppress metastasis of mouse lung cancer cells.
To assess the potential toxicity of the PEI/miR-708-
5p treatment, we exposed healthy mice upon the complex 
using the same dosing regimen as described in the above 
therapy study. Intravenous delivery of PEI/miR-708-5p 
increased miR-708-5p levels in liver tissues, whereas the 
PEI/control did not modulate miR-708-5p levels relative 
to PBS (Supplementary Figure S6A). All three groups of 
mice tolerated the procedure well and exhibited normal 
behaviours. Body weights were not affected by the PEI/
miR-708-5p treatment (Supplementary Figure S6B). 
Histo-pathological examination of the livers revealed 
no steatosis, portal or lobular inflammation, necrosis, 
fibrosis, nor biliary change in any of the three groups 
(Supplementary Figure S6C). White blood cells (WBC) 
and lymphocytes (LYMPH) in the PEI/miR-708-5p group 
of mice showed a slight decrease, but remained in the 
normal range when compared to both the PBS group and 
PEI/control group (Figure 6D). Also, a cell cycle and 
proliferation assay showed that miR-708-5p has no effect 
on the growth of normal human lung cell WI-38 in vitro 
(Supplementary Figure S6D, S6E). Thus, the PEI/miR-
708-5p treatment involves no apparent toxic effects on the 
treated animals and normal human cells. 
DISCUSSION
This article provides the first report of miR-708-
5p as an anti-metastatic miRNA and a direct negative 
regulator of the cyclin-dependent kinase inhibitor, p21, in 
human non-small cell lung cancers. It demonstrates that 
miR-708-5p can suppress not only total p21, but also the 
cytoplasmic localization of p21, which in turn elevates 
apoptosis and weakens actin rearrangement, leading to 
decreased cell motility (Figure 6E). Moreover, miR-708-
5p suppresses both the stem cell like properties of lung 
cancer cells and the PI3K/AKT pathway. For its dual roles 
in anti-metastasis and conferring anti-stem cell properties, 
miR-708-5p is proposed here to be a suitable candidate 
for miRNA replacement therapy. The in vivo miR-708-5p 
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Figure 5: miR-708-5p inhibits the metastasis related pathway and stem cell markers. (A) The functional annotation clusters 
in universal genes differentially expressed in the A549 cells treated with miR-708-5p or control mimics. The annotation clusters were 
predicted from RNA-seq data of the cells by use of the DAVID. (B) The differential expression of PI3K pathway related genes identified 
in the deep sequencing data was confirmed in the miR-708-5p overexpressing A549, H1299, PG cells and their control cells by qRT-PCR. 
β-actin was used as a normalized control, and *P < 0.05, **P < 0.01. (C) The differentially expressed metastasis-related genes identified 
in the deep sequencing data were confirmed in the miR-708-5p overexpressing A549, H1299, PG cells and their control cells by qRT-PCR. 
β-actin was used as a normalized control, and *P < 0.05, **P < 0.01, ***P < 0.001. (D) The differentially expressed stem cell marker genes 
identified from the deep sequencing data were confirmed in the miR-708-5p overexpressing A549, PG cells and their control cells by qRT-
PCR. β-actin was used as a normalized control, and *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 6: Anti-tumor assays of the replacement therapy for PEI/miR-708-5p treatment in the A549 lung cancer mouse 
model. (A) The A549 cells were subcutaneously injected into nude mice to form solid tumors, and then intra-tumorous delivery of the 
PEI/miR-708-5p was conducted continuously for 3 weeks. Generated subcutaneous tumors in the right and left flank areas, where the right 
subcutaneous tumors were injected with the PEI/miR-708-5p and the left tumors with PEI/control, were compared with each other. Upper: 
representative images of mice before intra-tumorous injections were started. Middle: representative images of mice and subcutaneous 
tumors dissected at day 25 after the PEI/miR-708-5p treatment.  Lower:  means and s.d. of weight of subcutaneous tumors after intra-
tumoral injections (n = 5 for each group). (B) Immunohistochemical staining of p21, pT145-p21, active caspase-3, Oct-4 in tumor tissues 
dissected from nude mice treated with the PEI/miR-708-5p or PEI/control. Scale bars, 80 µm. (C) Metastasis of the A549 lung cancer cells 
after the PEI/miR-708-5p replacement treatment. Left: Presented are bioluminescence images of animals showing lung metastasis at day 
25 after PEI/miR-708-5p replacement treatment. The treatments were intravenously delivered twice weekly for 3 weeks, starting at 3 day 
or 10 day after tumor cell implantation. The color scale bar depicts the photon flux (photons per second) emitted from these mice. Right: 
Quantitation of lung metastases assessed by bioluminescences measurements (n = 6 per group). Data represent mean ± s.d. (D) Toxicity 
assessment of intravenous delivery of PEI/miR-708-5p, PEI/control or PBS in normal mice. White blood cell (WBC) and lymphocyte 
(LYMPH) count. Data were presented as mean and s.d. (n = 6 per group). (E) A proposed model for the miR-708-5p-mediated pathway 
regulating NSCLC metastasis.
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restoration in the lung tumor xenografts by intra-tumorous 
delivery has been found to restore normalcy and inhibit 
tumor formation in the lung cancer mouse model. 
Likewise, restoration of miR-708-5p does also inhibit 
metastasis in the mouse lung metastasis model. 
Despite significant advances in cancer therapy over 
the past 50 years, developing treatments for metastatic solid 
cancers remains one of the greatest challenges in modern 
clinical cancer research. Survival of patients with such 
malignancies is typically limited to months only. In the era 
of targeted therapy, a prominent and well-defined role of 
the PI3K/AKT pathway in modulating cancer cell growth 
and survival has motivated development of PI3K/AKT 
pathway inhibitors as a promising and effective therapy for 
malignant solid cancers [27, 32]. This therapeutic strategy 
has been developed into several successful clinical and/or 
pharmaceutical applications [33–35]. But the limitation of 
these inhibitors lies in the development of drug resistance 
for the signaling feedback loop in cancer cells. Our RNA-
seq data shows that miR-708-5p impairs the PI3K/AKT 
pathway through down-regulating multiple receptor 
tyrosine kinases, such as the EGF receptor family genes 
and insulin receptor family genes, revealing that miR-708-
5p can inactivate the multiple feedback loop of the PI3K/
AKT pathway and may be substantially more effective 
than single-agent PI3K pathway inhibitors. miR-708-5p 
mediated replacement therapy may therefore represent 
a promising compensator or even an alternative to the 
current PI3K pathway inhibitors. In addition to inhibiting 
the PI3K pathway, miR-708-5p suppresses several other 
intracellular pathways, in turn inhibiting cancer stem 
cells, cancer cell migration and survival. These findings 
indicate that miR-708-5p may enable multiple antitumor 
effects by specifically interfering with several oncogenic 
pathways, thereby preventing tumor cells from escaping 
drug targeting. Furthermore, the cytoplasmic expression of 
p21 enables cancer cells to escape drug-induced apoptosis 
and can result in drug resistance during chemotherapeutic 
treatment [36–39]. Thus, if chemotherapeutic treatment of 
cancer cells could be integrated with use of a miR-708-5p 
mimic, the tumors may then become more susceptible to 
the drug targeting and apoptosis, improving the efficiency 
of chemotherapy.
PEI is the synthetic polymers, which are able to 
form non-covalent complexes with DNAs or RNAs. 
These nanoscale complexes enable protection of DNAs 
or RNAs from nucleolytic degradation, their efficient 
cellular uptake through endocytosis and intracellular 
release through the proton sponge effect [40]. Being 
nontoxic, linear PEI, one kind of PEI polymers, is under 
clinical trials [41]. This paper presents the first linear PEI-
based miRNA replacement therapy for lung cancer in a 
mouse model. Our data of systemic delivery of the PEI/
miR-708-5p complexes demonstrate that miR-708-5p 
expression in mouse lung cells was 4 to 6 folds higher 
than that in the liver cells, suggesting that PEI/miRNA 
is an efficient delivery platform for treatment of lung 
diseases with little or no systemic side effects. Also, the 
miR-708-5p replacement therapy experiment demonstrates 
that the PEI-dependent delivery of miRNAs into tumours 
represents an efficient therapeutic schedule for lung 
cancer. Despite the tested high efficacy of the miR-708-
5p mediated gene therapy, further knowledge about the 
PEI-based delivery systems may need to be accumulated 
before clinical trials will be initiated with humans.
MATERIALS AND METHODS
Cell lines and tissue samples 
Cell lines H520, H2170, H226, H1703, A549, 
H1299, and WI-38 were obtained from American Type 
Culture Collection and cultured under conditions provided 
by the manufacturer. Cell lines PG, 95C and QG56 were 
obtained from the Cell Bank of Type Culture Collection 
of the Chinese Academy of Science (CBTCCCAS, 
Shanghai). All the cells were authenticated by short 
tandem repeat DNA profiling upon initial receipt and 
periodically thereafter, and were propagated for less than 
6 months after resuscitation. These cells were cultured 
at 37°C under 5% CO2 in RPMI-1640 (Invitrogen) 
supplemented with 10% FBS (Thermo scientific), and 
penicillin/streptomycin (Thermo scientific).
72 NSCLC samples including 36 Adc and 36 Sqc, 
were collected between 2003 and 2008 at Shanghai 
pulmonary hospital in China. The clinicopathologic 
characteristics of patients were listed in Supplementary 
Table S1. Another 66 frozen human primary NSCLC 
tissues (28 Adc and 38 Sqc) were obtained at Xijing 
Hospital in 2013. Tumors were classified according to 
the World Health Organization pathologic classification 
system. All patients provided informed consent and did 
not receive any therapy before surgery. 
Antibodies 
Antibodies used in the present study are as 
following: p21 (Abcam), pT145-p21 (Abcam), AKT1 
(Santa Cruz), pS473-AKT1 (Santa Cruz), Vimentin 
(Abcam), β-catenin (Abcam), GAPDH (Abcam), β-actin 
(Sigma), cleaved PARP (Abcam), active caspase-3 
(Cell signaling), procaspase-3 (Abcam), Oct4 (Abcam), 
E-cadherin (R & D), S1PR1 (Abcam).
Isolation of RNA, reverse transcription and  
real-time PCR quantification  
Total RNA was extracted from frozen tissues or 
cultured cells using Trizol total RNA isolation reagent 
(Invitrogen), as the manufacturer’s instructions. cDNA 
was synthesized from total RNA or purified small RNAs 
using gene-specific primers or random hexamers with the 
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SUPERSCRIPT III Reverse Transcriptase Kit (Invitrogen), 
according to the manufacturer’s instructions. Real-time 
PCR was performed using an Applied Biosystems 7500. 
The relative expression level was calculated from a 
relative standard curve obtained by using log dilutions of 
cDNA containing the mRNA or miRNA of interest. The 
average of two independent analyses for each gene and 
sample was calculated and normalized to the endogenous 
reference control gene ACTIN or U6 small nuclear RNA.
miRNA/siRNA transfection 
Cells were planted in growth medium without 
antibiotics approximately 24 hours before transfections. 
Transient transfections of miRNA mimics/ antagomir/siRNA 
were carried out by using lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol. All miRNA 
mimic/antagormir/siRNA transfections were for 48 hours.
Lentivirus mediated cell transfection and 
transduction 
The miR-708-5p sponge was constructed with 
a method modified from previous reports [42]. To 
establish immortal cell lines with miR-708-5p sponge or 
control sponge, we employed a lentivirus-mediated cell 
transformation technique. Recombinant lentiviruses were 
produced by co-transfecting human embryonic kidney 
(HEK) 293T cells with the miR-708-5p-sponge lentiviral 
expression plasmid and packaging plasmids (delta 8.9 
and VSVG) using Lipofectamine 2000 (Invitrogen) as 
a transfection reagent. HEK 293T cells were cultured in 
DMEM supplemented with 10% FCS in a 37°C incubator 
with 5% CO2. Infectious lentiviruses were collected 48 h 
after transfection. The supernatant was centrifuged to 
remove cell debris and filtered through 0.45 μm filters 
(Millipore). Cells were infected with the collected lentivirus.
Luciferase assay 
For target gene assays, the 3′UTR of human p21 
was amplified using PCR and cloned into a pGL3 vector. 
Cells of 70% confluence in 24-well plates were transfected 
using Lipofectamine 2000. The constructed pGL3 vector 
(100 ng), 5 ng of pRL-SV40 Renilla luciferase construct 
(for normalization), and 100 ng of control mimics or 
miR-708-5p mimics were cotransfected per well. Cell 
extracts were prepared 36 h after transfection, and the 
luciferase activity was measured using the Dual luciferase 
reporter assay system (Promega).
Wound healing assay
Cells were seeded in 24-well plates and cultured 
until confluent. Cells were then serum-starved for 
overnight before wounding. The cell layers were scraped 
with a plastic pipette tip and washed three times with 
serum-free medium. The remaining cell was incubated 
24 h or 48 h to allow cells to migrate into the cleared 
space. To quantify cell migration, phase-contrast images 
of identical location in each wound were taken at 0 h, 
24 h and 48 h after wounding. The distance of cell 
migration was measured.
MTT assay for cell proliferation
Cells were grown in 96-well plants in volumes of 
200 μL of medium per well. MTT (5 mg/ml, Sigma) was 
added to each well in a volume of 20 μL. After a further 
period of incubation for 4 h at 37°C, the medium was 
aspirated from the wells as completely as possible without 
disturbing the formazan crystals, and 200 μL DMSO was 
added to each well. The plates were shaken for 10 min 
to dissolve the purple formazan crystals. Then the optical 
density was recorded using a micro-plate reader (Bio-Tek 
Instruments) at 570 nm.
Cell cycle analysis stained by PI 
Cells were suspended in 400 μL PI (Propidium 
Iodide)/Triton X-100 staining solution and incubated 
37°C for 15 minutes, then detected by flow cytometer 
(BD Biosciences). PI/Triton X-100 staining solution: 
0.1% (V/V) Triton X-100 (Sigma) in PBS add DNase-free 
RNase A (Sigma) and 500 μg/ml PI (Sigma). 
Migration and invasion assays 
In vitro cell migration assays were performed 
as described previously using Trans-well chambers 
(8 μM pore size; Costar). Cells were allowed to grow to 
subconfluency (~75–80%) and were serum-starved for 
24 h. After detachment with trypsin, cells were washed 
with PBS and resuspended in serum-free medium. Next, 
100 μl cell suspension (2 × 106 cells/mL) was added to 
the upper chamber. Complete medium was added to the 
bottom wells of the chambers. For the screen, the cells that 
had not migrated after 24 h were removed from the upper 
face of the filters using cotton swabs, but the cells that 
had migrated were fixed with 5% glutaraldehyde solution 
to determine the number of migratory cells. The lower 
surfaces of the filters were stained with 0.25% Trypan 
Blue. Images of six different × 10 fields were captured 
from each membrane and the number of migratory cells 
was counted. The mean of triplicate assays for each 
experimental condition was used. Similar inserts coated 
with Matrigel were used to evaluate cell invasive potential 
in the invasion assay.
Immunoblotting 
Total protein was separated by 10~15% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis and 
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transferred to PVDF membranes. After blocking in 5% 
nonfat milk, the membrane was incubated with the primary 
antibodies, prior to washing and exposure to peroxidase-
conjugated secondary antibodies. Ultimately, the membrane 
was treated with chemiluminescence reagents (Santa Cruz) 
as per the manufacturer’s instructions, and the image was 
developed on X-ray films.
Apoptosis assays 
FACS analysis for apoptosis was done 72 hours after 
transfection, using Annexin V-FLOUS/PI Kit (Roche), 
according to the manufacturer’s protocol. Stained cells 
were immediately analyzed with a flow cytometer (BD 
Biosciences).
Actin stress fiber staining and 
immunocytochemistry 
Cells were grown on glass coverslips for 24 h and 
serum starved for 48 h, then stimulated by exposure to 10% 
serum for 6 h. Cells were fixed in 4% paraformaldehyde 
for 20 min and permeabilized with 0.1% Triton X-100 
for 15 min at room temperature. The coverslips were 
incubated in the dark with pT145-p21 antibody (Abcam) 
at 4°C overnight, then counterstaining with FITC goat 
secondary antibodies. Next, the coverslips were incubated 
with 100 nM rhodamine phalloidin (Cytoskeleton) at room 
temperature for 30 min. Nuclei were counterstained with 
100 nM DAPI. The coverslips were rinsed in PBS and 
inverted on a drop of anti-fade mounting media on a glass 
slide. Then these slides were sealed with nail polish and 
viewed under the confocal microscope. 
Immunohistochemistry 
Paraffin sections were deparaffinized. Immunostaining 
using monoclonal antibodies p21, pT145-p21, active 
caspase-3 and Oct-4 were performed according to the 
methods provided in the immunoCruz Staining System 
Kit (Santa Cruz Biotechnology). Briefly, hydrated tissue 
sections were steamed for 30 min in 0.1% citrate acid and 
blocked in serum for 20 min at room temperature. Samples 
were subsequently incubated with the indicated antibody for 
1 h and with biotinylated secondary antibody for 30 min, 
and then visualized using chromogen 3′3′-diaminobenzidine 
(DAB). Slides were counterstained with Mayer’s 
hematoxylin for 20 sec and rinsed abundantly in H2O 
before dehydration and mounting. 
Coimmunoprecipitations
A549 and PG cells synchronized by serum 
deprivation for 48 h were restimulated by exposure to 
10% serum for 6 h. Cells were lysed in 500 μL lysis buffer 
(cell signaling) for a 100 mm plate. For each IP, 1 μg of 
the appropriate antibody, 2 mg lysate proteins, and 20 μL 
of protein A sepharose beads (Amersham) were incubated 
for 3 h at 4°C. Immunoprecipitates were rinsed three times 
in lysis buffer, and 10 μL of 4 × sample buffer was added 
to the bead pellet. Immunoprecipitates, as well as 10 μL 
of the corresponding lysates for protein loading, were 
subjected to immunoblotting as described above.
RNA-seq library construction, sequencing and 
data analysis 
Total RNA was evaluated the integrity and 
concentration using Agilent Technologies 2100 
bioanalyzer. For each sample, 2 ug of total RNA with a 
RIN value more than 8.0, was imputed into the procedure 
of RNA-seq library preparation as per Illumina TruSeq 
RNA Sample Preparation protocol. RNA-seq libraries 
were sequenced using the Illumina HiSeq 2000 instrument 
as per manufacturer’s instructions. Sequencing of libraries 
was performed up to 2 × 101 cycles. Image analysis and 
base calling were performed with the standard Illumina 
pipeline version RTA 2.8.0.
The sequencing reads containing either N over 3% 
or low quality bases (< 18) over 50% of the full length 
in each end were removed. All the clean reads were then 
aligned to the UCSC (the University of California Santa) 
Homo sapiens reference genome using TopHat v1.3.3 
with default parameters [43]. The expression levels of 
the transcripts were quantified by Mapped Fragments 
per Kilobase of Exon model per Million mapped reads 
(FPKM) using Cufflinks [44]. Differential expression 
gene was identified with the output q ≥ 0.8 using non-
parameter test provided by NOISeq [45]. The panel of 
differential expression genes was performed functional 
clustering and enrichment analyses using the Database 
for Annotation, Visualization and Integrated Discovery 
(DAVID) [29].
Mouse experiments 
All animal experiments were performed according 
to the protocol of the Fudan Committee on Animal Care 
using six-week-old to eight-week-old female BALB/c 
nude mice. 6×106 QG56 cells transduced with miR-708-5p 
sponge or control sponge were injected into the caudal 
vein. Lung metastatic colonization was monitored and 
quantified after 8 weeks. Each group was comprised of 
6 mice unless otherwise stated.
To examine the antitumor effects of miR-708-5p, 
nude mice (n = 5) received subcutaneous injections of 
3 × 106 A549 cells in the right and left flank areas in a 
volume of 100 µL. When tumors reached an average 
volume of 50 to 100 mm3, 10 µg of synthetic miRNA 
(miR-708-5p or control) mimics (Genephama, China) 
mixed with 1.2 µL of in vivo jet polyethylenimine (PEI) 
transfection reagent (Polyplus Transfection, France) was 
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delivered intra-tumorously twice a week for 3 weeks. 
Mice were sacrificed after the last treatment, and the 
tumors generated were used in further analysis. PEI is one 
of the promising polycations because it condenses RNA or 
DNA and the resulting PEI/RNA (PEI/DNA) complex can 
act as proton sponge, thus enabling RNA or DNA delivery 
into cytoplasm via endosomes.
To assess the anti-metastatic effects of miR-708-5p, 
nude mice were implanted with A549 cells (6 × 106 cells 
per mouse). The miRNA/PEI treatment started 3 days 
or 10 days after tumor cell implantation: miR-708-5p 
or control mimics (40 µg) mixed with 4.8 µL of in vivo 
jet PEI were injected via the tail vein, twice weekly for 
3 weeks. Pulmonary metastases were monitored by live 
animal BLI (Xenogen IVIS system) 25 days after tumor 
cell implantation.
Statistical analysis 
All values were presented as mean ± standard 
deviation (SD), and Student’s t-test (two-tailed) was used 
to compare two independent groups. The Bartlett test and/
or Mann-Whitney-Wilcoxon test was implemented to 
evaluate differential expression of miR-708-5p between 
metastatic and non-metastatic lung cancer samples. 
Differences in patient characteristics between different 
miR-708-5p groups were tested with Kruskal-Wallis 
test. Expression data was normalized to the endogenous 
reference U6 before statistical analysis. Survival curves 
were plotted using the Kaplan-Meier method, and 
survival difference was assessed by the log-rank test 
using the median of each individual miRNA as a cutoff. 
P value < 0.05 was considered statistically.
ACKNOWLEDGMENTS 
We were approved by the Ethics Committee, School 
of Life Sciences Fudan University to conduct the study, 
and obtained written consent from all the patients who 
contributed tumor tissue samples analyzed here. We thank 
Dr. Yun Fan for his useful comments on an early version 
of the paper.
GRANT SUPPORT
The study was supported by the National 
Basic Research Program of China (grant number 
2012CB316505), the National Nature Science Foundation 
of China (grant numbers 81172006, 91231114, 31271335, 
31571343) and the Leverhulme Trust and BBSRC, United 
Kingdom to ZWL.
CONFLICTS OF INTEREST
The authors declare that they have no competing 
interests.
REFERENCES 
 1. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. 
Non-small-cell lung cancers: a heterogeneous set of 
diseases. Nat Rev Cancer. 2014; 14:535–546.
 2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. 
N Engl J Med. 2008; 359:1367–1380.
 3. Steeg PS. Tumor metastasis: mechanistic insights and 
clinical challenges. Nat Med. 2006; 12:895–904.
 4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, 
and function. Cell. 2004; 116:281–297.
 5. Alvarez-Garcia I, Miska EA. MicroRNA functions in 
animal development and human disease. Development. 
2005; 132:4653–4662.
 6. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, 
Thomson AM, Lim B, Riqoutsos I. A pattern-based method 
for the identification of microRNA binding sites and their 
corresponding heteroduplexes. Cell. 2006; 126:1203–1217.
 7. Inui M, Martello G, Piccolo S. MicroRNA control of signal 
transduction. Nat Rev Mol Cell Biol. 2010; 11:252–263.
 8. Kasinski AL, Slack FJ. Epigenetics and genetics. 
MicroRNAs en route to the clinic: progress in validating 
and targeting microRNAs for cancer therapy. Nat Rev 
Cancer. 2011; 11:849–864.
 9. Ling H, Fabbri M, Calin GA. MicroRNAs and other 
non-coding RNAs as targets for anticancer drug 
development. Nat Rev Drug Discov. 2013; 12:847–865.
10. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an 
in vivo model of microRNA-21-induced pre-B-cell 
lymphoma. Nature. 2010; 467:86–90.
11. Obad S, dos Santos CO, Petri A, Heidenblad M, 
Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, 
Hansen HF, Koch T, Pappin D, et al. Silencing of microRNA 
families by seed-targeting tiny LNAs. Nat Genet. 
2011; 43:371–378.
12. Williams M, Kirschner MB, Cheng YY, Hanh J, Weiss J, 
Mugridge N, Wright CM, Linton A, Kao SC, Edelman JJ, 
Vallely MP, McCaughan BC, Cooper W, et al. miR-
193a-3p is a potential tumor suppressor in malignant 
pleural mesothelioma. Oncotarget. 2015; 6:23480–95. 
doi:10.18632/oncotarget.4346.
13. Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, 
Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, 
Mischel PS, et al. Tumor-suppressive miR148a is silenced 
by CpG island hypermethylation in IDH1-mutant gliomas. 
Clin Cancer Res. 2014; 20:5808–5822.
14. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-
Céspedes M, Blanco D, Montuenga LM, Rossi S, 
Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, 
Croce CM, et al. A microRNA DNA methylation signature 
for human cancer metastasis. Proc Natl Acad Sci USA. 
2008; 105:13556–13561.
Oncotarget2431www.impactjournals.com/oncotarget
15. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, 
Lindow M, Munk ME, Kauppinen S, Ørum H. Therapeutic 
silencing of microRNA-122 in primates with chronic 
hepatitis C virus infection. Science. 2010; 327:198–201.
16. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, 
Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, 
Slack FJ. Regression of muring lung tumors by the let-7 
microRNA. Oncogene. 2010; 29:1580–1587.
17. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, 
Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. 
RAS is regulated by the let-7 microRNA family. Cell. 
2005; 120:635–647.
18. vanRooij E, Sutherland LB, Qi X, Richardson JA, 
Hill J, Olson EN. Control of stress-dependent cardiac 
growth and gene expression by a microRNA. Science. 
2007; 316:575–579.
19. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, 
Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN, van 
Rooij E. Therapeutic inhibition of miR-208a improves 
cardiac function and survival during heart failure. 
Circulation. 2011; 124:1537–1547.
20. Wu X, Liu T, Fang O, Leach LJ, Hu X, Luo Z. MiR-194 
suppresses metastasis of non-small cell lung cancer through 
regulating expression of BMP1 and p27(kip1). Oncogene. 
2014; 33:1506–1514.
21. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-
mesenchymal transitions in development and disease. Cell. 
2009; 139:871–890.
22. Lamouille S, Xu J, Derynck R. Molecular mechanisms of 
epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 
2014; 15:178–196.
23. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, 
Fukumuro K, Mizutani S. Apoptosis inhibitory activity of 
cytoplasmic p21Cip1/WAF1 in monocytic differentiation. 
EMBO J. 1999; 18:1223–1234.
24. Tanaka H, Yamashita T, Asada M, Mizutani S, Yoshikawa H, 
Tohyama M. Cytoplasmic p21Cip1/WAF1 regulates neurite 
remodelling by inhibiting Rho-kinase activitiy. J Cell Biol. 
2002; 158:321–329.
25. Ridley AJ, Hall A. The small GTP-binding protein rho 
regulates the assembly of focal adhensions and actin 
stress fibers in response to growth factors. Cell. 
1992; 70:389–399.
26. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. 
Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced 
phosphorylation in HER-2/neu-overexpressing cells. Nat 
cell boil. 2001; 3:245–252.
27. Engelman JA. Targeting PI3K signalling in cancer: 
opportunities, challenges and limitations. Nat Rev Cancer. 
2009; 9:550–562.
28. Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M. 
Resistance to Fas-mediated apoptosis: activation of 
Caspase-3 is regulated by cell cycle regulator p21WAF1 and 
IAP gene family ILP. Oncogene. 1998; 17:931–939.
29. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, 
Lane HC, Lempicki RA. DAVID: Database for annotation, 
visualization, and integrated discovery. Genome Biol. 
2003; 4:P3.
30. Visvader JE, Lindeman GJ. Cancer stem cells in solid 
tumours: accumulating evidence and unresolved questions. 
Nat Rev Cancer. 2008; 8:755–768.
31. Phillips TM, McBride WH, Pajonk F. The response of 
CD24−/low/CD44+ breast cancer-initiating cells to radiation. 
J Natl Cancer Inst. 2006; 98:1777–1785.
32. Polivka JJ, Janku F. Molecular targets for cancer therapy 
in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 
2014; 142:164–175.
33. Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, 
Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, 
Rudoltz M, Mone M, Gathmann I, Hughes TP, et al. Six-
year follow-up of patients receiving imatinib for the first-
line treatment of chronic myeloid leukemia. Leukemia. 
2009; 23:1054–1061.
34. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, 
Press M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, 
Pinter T, Valero V, et al. Adjuvant trastuzumab in 
HER2-positive breast cancer. N Engl J Med. 2011; 
365:1273–1283.
35. Muhsin M, Graham J, Kirkpatrick P. Gefitinib. Nat Rev 
Drug Discov. 2003; 2:515–516.
36. Fan Y, Borowsky AD, Weiss RH. An antisense 
oligodeoxynucleotide to p21Waf1/Cif1 causes apoptosis 
in human breast cancer cells. Mol Cancer Ther. 2003; 
2:773–782.
37. Liu S, Bishop WR, Liu M. Differential effects of cell 
cycle regulatory protein p21WAF1/Cip1 on apoptosis and 
sensitivity to cancer chemontherapy. Drug Resist Updat. 
2003; 6:183–195.
38. De la Cueva E, García-Cao I, Herranz M, López P, García-
Palencia P, Flores JM, Serrano M, Fernandez-Pigueras J, 
Martin-Caballero J. Tumorigenic activity of p21Waf1/Cip1 
in thymic lymphoma. Oncogene. 2006; 25:4128–4132.
39. Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, 
Ford HL. EWS/FLI1 regulates EYA3 in Ewing Sarcoma 
via modulation of miRNA-708, resulting in increased 
cell survival and chemoresistance. Mol Cancer Res. 
2012; 10:1098–1108.
40. Patnaik S, Gupta KC. Novel polyethylenimine-derived 
nanoparticles for in vivo gene delivery. Expert Opin Drug 
Del. 2013; 10:215–228.
41. Sidi AA, Ohana P, Benjamin S, Shalev M, Ransom JH, 
Lamm D, Hochberg A, Leibovitch I. Phase I/II marker 
lesion study of intravesical BC-819 DNA plasmid in H19 
over expressing superficial bladder cancer refractory to 
bacillus Calmette-Guerin. J Urol. 2008; 180:2379–2383.
42. Eber MS, Neilson JR, Sharp PA. MicroRNA sponges: 
competitive inhibitors of small RNAs in mammalian cell. 
Nat Methods. 2007; 4: 721–726.
Oncotarget2432www.impactjournals.com/oncotarget
43. Trapnell C, Pachter L, Salzerg SL. TopHat: discovering splice 
junctions with RNA-Seq. Bioinformatics. 2009; 25:1105–1111.
44. Trapnell C, Williams BA, Pertea G, Mortazavi A, 
Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. 
Transcript assembly and quantification by RNA-Seq reveals 
unannotated transcripts and isoform switching during cell 
differentiation. Nat Biotechnol. 2010; 28:511–515.
45. Tarazona S, Garcia-Alcalde F, Dopazo J, Ferrer A, 
Conesa A. Differential expression in RNA-seq: a matter of 
depth. Genome Res. 2011; 21:2213–2223.
